Construction and characterization of single-chain antibodies against human insulin-like growth factor-I receptor from hybridomas producing 1H7 or 3B7 monoclonal antibody

Yu Kusada, Toru Morizono, Ayano Matsumoto-Takasaki, Keiko Sakai, Shuma Sato, Hideki Asanuma, Atsushi Takayanagi, Yoko Fujita-Yamaguchi

研究成果: Article

7 引用 (Scopus)

抄録

Recombinant antibody consisting of the single-chain variable fragment (scFv) of 1H7 monoclonal antibody against insulin-like growth factor-I receptor (IGF-IR) and human IgG1 Fc domain, scFv-Fc, has been found to exhibit inhibitory effects on breast cancer growth in vitro and in vivo [Li et al. (2000) Cancer Immunol. Immunother. 49, 243; Sachdev et al. (2003) Cancer Res. 63, 627]. Various types of scFvs from hybridomas producing 1H7 or 3B7 mAb were constructed using conventional phage display technology to further characterize the specificity and affinity of anti-IGF-IR mAbs. Binding studies performed using either phage antibodies or soluble scFv proteins to IGF-IR or insulin receptor (IR) and IGF-IR pre-incubated with mAbs suggested that (i) 1H7 and 3B7 bind to IGF-IR but do not bind to its structurally related IR, (ii) either the VL-VH or VH-VL sequence order does not apparently affect specificity for IGF-IR and (iii) 1H7 and 3B7 bind the independent epitopes, located in or near the N-terminal (440-514) and C-terminal (62-184) domains of the α subunit, respectively. This study not only revealed new information on binding regions for two anti-IGF-IR mAbs, but also provided the scFv genes as tools for further manipulation of the affinity or development of new IGF-IR-targeted cancer therapeutics.

元の言語English
ページ(範囲)9-19
ページ数11
ジャーナルJournal of Biochemistry
143
発行部数1
DOI
出版物ステータスPublished - 2008 1

Fingerprint

Single-Chain Antibodies
IGF Type 1 Receptor
Hybridomas
Monoclonal Antibodies
Bacteriophages
Insulin Receptor
Neoplasms
Epitopes
Immunoglobulin G
Genes
Display devices
Breast Neoplasms
Technology
Antibodies
Growth

ASJC Scopus subject areas

  • Biochemistry

これを引用

Construction and characterization of single-chain antibodies against human insulin-like growth factor-I receptor from hybridomas producing 1H7 or 3B7 monoclonal antibody. / Kusada, Yu; Morizono, Toru; Matsumoto-Takasaki, Ayano; Sakai, Keiko; Sato, Shuma; Asanuma, Hideki; Takayanagi, Atsushi; Fujita-Yamaguchi, Yoko.

:: Journal of Biochemistry, 巻 143, 番号 1, 01.2008, p. 9-19.

研究成果: Article

Kusada, Y, Morizono, T, Matsumoto-Takasaki, A, Sakai, K, Sato, S, Asanuma, H, Takayanagi, A & Fujita-Yamaguchi, Y 2008, 'Construction and characterization of single-chain antibodies against human insulin-like growth factor-I receptor from hybridomas producing 1H7 or 3B7 monoclonal antibody', Journal of Biochemistry, 巻. 143, 番号 1, pp. 9-19. https://doi.org/10.1093/jb/mvm192
Kusada, Yu ; Morizono, Toru ; Matsumoto-Takasaki, Ayano ; Sakai, Keiko ; Sato, Shuma ; Asanuma, Hideki ; Takayanagi, Atsushi ; Fujita-Yamaguchi, Yoko. / Construction and characterization of single-chain antibodies against human insulin-like growth factor-I receptor from hybridomas producing 1H7 or 3B7 monoclonal antibody. :: Journal of Biochemistry. 2008 ; 巻 143, 番号 1. pp. 9-19.
@article{0318526ff6f6421e94143211c0a6e0f4,
title = "Construction and characterization of single-chain antibodies against human insulin-like growth factor-I receptor from hybridomas producing 1H7 or 3B7 monoclonal antibody",
abstract = "Recombinant antibody consisting of the single-chain variable fragment (scFv) of 1H7 monoclonal antibody against insulin-like growth factor-I receptor (IGF-IR) and human IgG1 Fc domain, scFv-Fc, has been found to exhibit inhibitory effects on breast cancer growth in vitro and in vivo [Li et al. (2000) Cancer Immunol. Immunother. 49, 243; Sachdev et al. (2003) Cancer Res. 63, 627]. Various types of scFvs from hybridomas producing 1H7 or 3B7 mAb were constructed using conventional phage display technology to further characterize the specificity and affinity of anti-IGF-IR mAbs. Binding studies performed using either phage antibodies or soluble scFv proteins to IGF-IR or insulin receptor (IR) and IGF-IR pre-incubated with mAbs suggested that (i) 1H7 and 3B7 bind to IGF-IR but do not bind to its structurally related IR, (ii) either the VL-VH or VH-VL sequence order does not apparently affect specificity for IGF-IR and (iii) 1H7 and 3B7 bind the independent epitopes, located in or near the N-terminal (440-514) and C-terminal (62-184) domains of the α subunit, respectively. This study not only revealed new information on binding regions for two anti-IGF-IR mAbs, but also provided the scFv genes as tools for further manipulation of the affinity or development of new IGF-IR-targeted cancer therapeutics.",
keywords = "Epitope specificity, Insulin receptor, Insulin-like growth factor I receptor, Phage display, Single-chain antibody",
author = "Yu Kusada and Toru Morizono and Ayano Matsumoto-Takasaki and Keiko Sakai and Shuma Sato and Hideki Asanuma and Atsushi Takayanagi and Yoko Fujita-Yamaguchi",
year = "2008",
month = "1",
doi = "10.1093/jb/mvm192",
language = "English",
volume = "143",
pages = "9--19",
journal = "Journal of Biochemistry",
issn = "0021-924X",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - Construction and characterization of single-chain antibodies against human insulin-like growth factor-I receptor from hybridomas producing 1H7 or 3B7 monoclonal antibody

AU - Kusada, Yu

AU - Morizono, Toru

AU - Matsumoto-Takasaki, Ayano

AU - Sakai, Keiko

AU - Sato, Shuma

AU - Asanuma, Hideki

AU - Takayanagi, Atsushi

AU - Fujita-Yamaguchi, Yoko

PY - 2008/1

Y1 - 2008/1

N2 - Recombinant antibody consisting of the single-chain variable fragment (scFv) of 1H7 monoclonal antibody against insulin-like growth factor-I receptor (IGF-IR) and human IgG1 Fc domain, scFv-Fc, has been found to exhibit inhibitory effects on breast cancer growth in vitro and in vivo [Li et al. (2000) Cancer Immunol. Immunother. 49, 243; Sachdev et al. (2003) Cancer Res. 63, 627]. Various types of scFvs from hybridomas producing 1H7 or 3B7 mAb were constructed using conventional phage display technology to further characterize the specificity and affinity of anti-IGF-IR mAbs. Binding studies performed using either phage antibodies or soluble scFv proteins to IGF-IR or insulin receptor (IR) and IGF-IR pre-incubated with mAbs suggested that (i) 1H7 and 3B7 bind to IGF-IR but do not bind to its structurally related IR, (ii) either the VL-VH or VH-VL sequence order does not apparently affect specificity for IGF-IR and (iii) 1H7 and 3B7 bind the independent epitopes, located in or near the N-terminal (440-514) and C-terminal (62-184) domains of the α subunit, respectively. This study not only revealed new information on binding regions for two anti-IGF-IR mAbs, but also provided the scFv genes as tools for further manipulation of the affinity or development of new IGF-IR-targeted cancer therapeutics.

AB - Recombinant antibody consisting of the single-chain variable fragment (scFv) of 1H7 monoclonal antibody against insulin-like growth factor-I receptor (IGF-IR) and human IgG1 Fc domain, scFv-Fc, has been found to exhibit inhibitory effects on breast cancer growth in vitro and in vivo [Li et al. (2000) Cancer Immunol. Immunother. 49, 243; Sachdev et al. (2003) Cancer Res. 63, 627]. Various types of scFvs from hybridomas producing 1H7 or 3B7 mAb were constructed using conventional phage display technology to further characterize the specificity and affinity of anti-IGF-IR mAbs. Binding studies performed using either phage antibodies or soluble scFv proteins to IGF-IR or insulin receptor (IR) and IGF-IR pre-incubated with mAbs suggested that (i) 1H7 and 3B7 bind to IGF-IR but do not bind to its structurally related IR, (ii) either the VL-VH or VH-VL sequence order does not apparently affect specificity for IGF-IR and (iii) 1H7 and 3B7 bind the independent epitopes, located in or near the N-terminal (440-514) and C-terminal (62-184) domains of the α subunit, respectively. This study not only revealed new information on binding regions for two anti-IGF-IR mAbs, but also provided the scFv genes as tools for further manipulation of the affinity or development of new IGF-IR-targeted cancer therapeutics.

KW - Epitope specificity

KW - Insulin receptor

KW - Insulin-like growth factor I receptor

KW - Phage display

KW - Single-chain antibody

UR - http://www.scopus.com/inward/record.url?scp=38849099662&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38849099662&partnerID=8YFLogxK

U2 - 10.1093/jb/mvm192

DO - 10.1093/jb/mvm192

M3 - Article

C2 - 17956902

AN - SCOPUS:38849099662

VL - 143

SP - 9

EP - 19

JO - Journal of Biochemistry

JF - Journal of Biochemistry

SN - 0021-924X

IS - 1

ER -